Sodium-glucose cotransporter-2 inhibitors have shown class-effect signals in improving morphological features of plaque vulnerability in early noninvasive and invasive imaging studies; however, these findings are limited by their observational nature.87 Concurrently, randomized clinical trial data on glucagon-like peptide-1 receptor agonists are accumulating, demonstrating cardiovascular benefits, particularly in reducing myocardial infarction.88 The role of these novel compounds in plaque modification warrants dedicated investigation. Here, GLP1R is linked to myocardial infarction.